STATCenter·
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
An exemption for a common kind of biopharma deal is at the heart of disagreements over the proposal.
Read at STAT →
Health · 1 sources covering this
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
An exemption for a common kind of biopharma deal is at the heart of disagreements over the proposal.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/bd5453cae82d661652b91c154da8c546781dd2f5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Biopharma industry at odds over impact of Treasury’s new China rule"></iframe>
